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Mcm2–7 (MCM) proteins are part of the origin licensing machinery that regulates initiation of DNA replication. Geminin is a licensing
repressor and prevents reinitiation of DNA replication during S–G2–M phase by blocking reloading of Mcm2–7 at replication
origins. Here, we have analysed these replication licensing factors (RLFs) to determine whether the pathway becomes deregulated
during mammary carcinogenesis, and have assessed their potential value as prognostic markers. Protein expression profiles were
generated for Ki67, Mcm2, geminin, HER-2, ER and PR in a series of reduction mammoplasty (n¼18) and breast cancer specimens
(n¼120), and compared to clinicopathological parameters. A large proportion of epithelial cells of the terminal duct lobular unit
reside in a primed ‘replication licensed’ but not proliferating state. This state is characterised by Mcm2 expression and absence of Ki67
and the S/G2/M marker geminin. In breast cancers, increasing tumour grade is associated with increased Ki67, Mcm2 and geminin
expression. The Mcm2/Ki67 ratio decreases through the grades, indicating a shift from a predominantly licensed state to an actively
proliferating state. This shift is associated with an increase in the geminin/Ki67 ratio, signifying a shortening of G1 phase in breast
cancer cells. Ki67, Mcm2 and the Mcm2/Ki67 ratio are statistically significantly associated with the Nottingham Prognostic Index (NPI),
but geminin and the geminin/Ki67 ratio are not. Ki67, Mcm2 and Mcm2/Ki67 are highly correlated with one another, with Mcm2 being
the single most important predictor of NPI score (Po0.001). However, only 12% of variation in NPI is explained by Mcm2, as the
labelling index for this marker is approaching 100% for many of the high-grade tumours. The origin licensing phenotypes of normal
breast and breast cancers therefore relate to their cellular differentiation status, and high-level MCM expression in more poorly
differentiated tumours severely constrains their use as prognostic markers in breast cancer.
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With one million new cases in the world each year, breast cancer is
the most common malignancy in women and comprises 18% of all
female cancers. In the UK, breast cancer accounts for more than
14000 deaths each year and the incidence is increasing with a
prevalence of nearly 2% (McPherson et al, 2000). In spite of being
one of the most aggressive cancers in women worldwide, there are
encouraging signs that improvement in the mortality rate may be
possible through earlier diagnosis and improved therapeutic
interventions (Mori et al, 2002). Breast cancer is a complex
disease due to its morphological and biological heterogeneity, its
tendency to acquire chemo-resistance and the existence of several
molecular mechanisms underlying its pathogenesis (Mori et al,
2002). Half of the women who receive loco-regional treatment for
breast cancer will never relapse, whereas the other half will
eventually die from metastatic disease (Bundred, 2001). It is
therefore imperative to distinguish clearly between these two
groups of patients for optimal clinical management. Unfortunately,
prognostic markers for breast cancer are at present limited. The
most widely used prognostic indicator is the Nottingham
Prognostic Index (NPI), which combines the traditional and most
important independent predictors of outcome including tumour
size, histological grade and lymph node stage (Rampaul et al,
2001).
The initiation of DNA synthesis is a final and critical step in
growth control and is therefore of importance in carcinogenesis.
Initiation of eukaryotic DNA replication is dependent on the
assembly onto chromatin of prereplicative complexes (pre-RCs)
containing the origin recognition complex (ORC), Cdc6, Cdt1 and
Mcm2–7 proteins (Bell and Dutta, 2002), thereby rendering
origins licensed for one round of DNA replication during S phase
(Mendez and Stillman, 2000; Blow and Hodgson, 2002; Dimitrova
et al, 2002). Pre-RCs are activated by cyclin dependent kinases
(CDK) and the Cdc7/ASK kinase, leading to recruitment of
elongation factors, Cdc45, DNA polymerases and RPA to origins
(Masai and Arai, 2002; Nishitani and Lygerou, 2002). The
recruitment of these factors results in unwinding of the DNA
helix and initiation of DNA synthesis (Lei and Tye, 2001).
Replication initiation is tightly coupled to removal of the license,
thus preventing re-licensing after origin firing. This step is critical,
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sas origins must fire once and only once in each cell cycle to ensure
genomic stability. To avoid re-licensing, mammalian cells have
adopted a number of mechanisms. These include the inactivation
of licensing factors during S–G2–M phase, a process controlled by
CDK activity, regulated proteolysis and changes in gene expres-
sion. A further important mechanism is the repression of origin
licensing by geminin (Nishitani and Lygerou, 2002). This repressor
acts by competitively binding to Cdt1, thereby blocking Mcm2–7
re-loading onto chromatin (McGarry and Kirschner, 1998;
Wohlschlegel et al, 2000; Quinn et al, 2001; Tada et al, 2001).
Using membrane elution, we have demonstrated for human cells
that geminin expression is restricted to the S, G2 and M phases
of the cell cycle, in keeping with its function of preventing
re-replication (Eward et al, 2004; Wharton et al, 2004).
The constituents of the pre-RC can be regarded as relay stations
coupling growth regulatory pathways with DNA replication,
thereby serving as novel biomarkers of growth (Williams and
Stoeber, 1999). We have shown that repression of origin licensing
is a ubiquitous route by which the proliferative capacity of
metazoan cells is lowered during exit from the mitotic cell cycle.
Withdrawal from cycle into quiescent (G0), differentiated or
senescent states is coupled to downregulation of Cdc6 and MCM
proteins. We have also demonstrated in a range of different
tumour types that deregulation of Mcm2–7 is an early event in
tumourigenesis, and have exploited these novel biomarkers of
growth in primary diagnosis, surveillance and prognosis (Williams
et al, 1998, 2004; Stoeber et al, 1999, 2001, 2002; Meng et al, 2001;
Wharton et al, 2004). These studies have shown that the superior
sensitivity of the MCM proteins over the standard proliferation
marker Ki67 resides in the fact that Mcm2–7 identify not only
cycling cells, but also noncycling cells with proliferative potential
(Stoeber et al, 2001). Interestingly, this particular replication
phenotype (Ki67 negative but MCM positive) is exhibited by
premenopausal breast (Stoeber et al, 2001) and primary oocytes
(Eward et al, 2004), resting tissues that retain proliferative capacity
and that can respond rapidly to growth stimuli.
Here we have investigated regulation of Mcm2 and geminin in
normal premenopausal breast to more precisely define the cell
cycle kinetics of this unusual tissue type, which undergoes rapid
periodic expansion. We have also analysed deregulation of the
replication licensing pathway during mammary tumourigenesis.
Expression of Mcm2 and geminin has been compared with
receptor status (HER-2, ER, PR) and the standard proliferation
marker Ki67 to investigate coupling between DNA replication
licensing and differentiation. Expression profiles of these new
molecular markers have been compared to clinicopathological
parameters to assess their prognostic value.
MATERIALS AND METHODS
Clinical specimens
Patients who had surgery for invasive breast cancer were identified
by a search of the histopathology records at University College
London, UK. Archival formalin-fixed, paraffin-embedded breast
tissue was retrieved from the archives of the Department of
Pathology for 120 cases of invasive breast cancer, which included
all three histological grades (1–3) calculated according to the
Nottingham modification of the Bloom and Richardson method
(Elston and Ellis, 2002). Histological reports and slides were
available for all cases. These included 93 invasive ductal
carcinomas, 20 lobular, four mucinous and three of mixed type.
The parameters studied were histological grade, tumour size,
tumour type, lymph node status, lymphovascular invasion (LVI),
age and NPI. We also studied randomly selected cases of normal
breast tissue from 18 women, 17 of whom had undergone
reduction mammoplasty and one a prophylactic mastectomy for
BRCA1. Local research ethics committee approval was obtained
from the joint UCL/UCLH Committees on the Ethics of Human
Research.
Antibodies
Mouse anti-human monoclonal Mcm2 antibody (clone 46) was
obtained from BD Transduction Laboratoriest (Lexington, KY,
USA). Mouse anti-human monoclonal Ki67 (clone Mib-1), mouse
monoclonal oestrogen receptor-a (clone 1D5) and mouse mono-
clonal progesterone receptor (clone PgR 636) antibodies were
obtained from DAKO (Glostrup, Denmark). Affinity-purified
rabbit polyclonal antibody G95 was generated against human
geminin as described (Wharton et al, 2004).
Immunohistochemistry
Sections (3mm) of formalin-fixed, paraffin-embedded tissues were
cut onto DAKO TechMatet S2024 charged slides, baked in a 601C
oven overnight to maximise section adhesion, dewaxed in xylene,
and rehydrated through a series of alcohol to water. For antigen
retrieval, tissues were pressure-cooked for 2min in 0.1 M citrate
buffer at pH 6.0. For ER, PR, Ki67, Mcm2 and geminin detection,
automatic immunostaining was performed on a DAKO TechMatet
500 as described (Dogan et al, 2000). Endogenous peroxidase
activity was quenched by incubating the sections with peroxidase
blocking solution (DAKO, S2023) for 10min. Sections were then
washed twice using Tris-buffered saline containing 0.1% Tween-20
(SIGMA, St Louis, USA) for this and subsequent washes. Slides
were incubated with primary antibodies for 1h at room
temperature using the following concentrations: ER (1/100), PR
(1/50), Ki67 (1/50), Mcm2 (1/1000), geminin (G95) (1/1000). After
washing, antigen-bound primary antibodies were detected with a
labelled streptavidin biotin detection system (DAKO ChemMatet
K5001). Slides were incubated with biotinylated secondary anti-
body (Ab2) for 30min. After washing sections were incubated with
streptavidin horseradish peroxidase for 30min. After washing, the
immunostain was developed applying 3,3-diaminobenzidine tetra-
hydrochloride (DAB) for 7min. HER-2 immunostaining was
performed using the DAKO HercepTestt (DAKO K5205), accord-
ing to the manufacturer’s instructions. Slides were counter-stained
with Mayer’s haematoxylin, differentiated in 1% acid alcohol,
dehydrated and cleared in xylene. Coverslips were applied with
Leica CV Mount (Leica, Nussloch, Germany). Primary antibodies
were omitted in negative controls and, in addition, appropriate
tissue sections were used as positive and negative controls.
Protein expression profile analysis
Slides were examined and 3–5 fields were captured with an
Olympus BX51 microscope/CCD camera setup using ANAlysis
software (SIS, Mu ¨nster, Germany). Captured images were printed
for quantitative analysis, and the labelling index (LI) for each
marker was calculated as the percentage of cells stained positive.
Cells were identified as positive if there was any nuclear staining
present and any stromal or inflammatory cells on the field were
excluded. A median of 400 cells was counted per slide. For
evaluation of HER-2 protein overexpression, membrane staining
was assessed following the criteria recommended by DAKO. Slides
were examined by three independent investigators (GHW, ML and
AS). GHW is a consultant histopathologist and re-examined all
cases analysed by ML and AS. This assessment of interobserver
variability showed high concordance.
Statistical analysis
Different statistical techniques were used to compare the expres-
sion of markers to grade, lymph node metastasis, tumour size, NPI,
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sand LVI. The Jonkheere–Terpstra test was used to examine
whether there was any association between marker expression and
grade. This is a nonparametric test, which takes into account the
ordering of the categories of grade. A logistic regression model was
used to analyse the relationship between marker expression and
lymph node metastasis. Spearman’s rank correlation coefficient
was used to examine the association between marker expression
and tumour size. Linear regression was used to model the
relationship between marker expression and NPI. A Mann–
Whitney test was used to examine the association between marker
expression and LVI.
RESULTS
DNA replication licensing and cell cycle kinetics of normal
resting breast tissue
We first studied expression of Mcm2, geminin, Ki67, and the ER
and PR hormone receptors in a series of normal breast specimens
(n¼18). As reported by ourselves and others (Stoeber et al, 2001;
Gonzalez et al, 2003), high-level Mcm2 expression was observed in
epithelial cells of the terminal duct lobular unit (TDLU) in normal
resting premenopausal breast (Table 1, Figure 1A and B). Whereas
the level of Mcm2 expression was high, Ki67 was expressed at low
levels (median Mcm2: 35.32% (range 4.9–98.43) compared to Ki67:
2.14% (range 0.22–35.32)). Geminin is present in only a minority
of cells in premenopausal breast (median: 0.76% (range 0–13.87)).
These data are in keeping with a high proportion of mammary
epithelial cells residing in a licensed MCM expressing but non-
proliferating state (Stoeber et al, 2001).
DNA replication licensing and cell cycle kinetics of breast
cancer
Next we asked whether DNA replication licensing is coupled to
cellular differentiation in breast cancer. To address this question,
we compared Ki67, Mcm2 and geminin expression with ER and PR
status in an invasive breast carcinoma series (n¼120, Table 2).
Expression profiles of replication licensing factors (RLFs) and
differentiation markers were compared with tumour size, grade,
lymph node status, vascular invasion and NPI. Median labelling
indices for each protein are shown in Table 1 and Figure 2, and
representative immunostained tissue sections are illustrated in
Figure 3. As part of the analysis, Mcm2/Ki67 and geminin/Ki67
ratios were also calculated for each tumour. Both Ki67 and Mcm2
are expressed throughout all four phases of the mitotic cell cycle
(G1, S, G2 and M). Mcm2–7 protein expression also identifies
noncycling cells with proliferative potential (Stoeber et al, 2001;
Eward et al, 2004; Wharton et al, 2004). The Mcm2/Ki67 ratio
therefore defines the proportion of cells that are licensed to
proliferate. Consequently, the higher the Mcm2/Ki67 ratio, the
greater the proportion of cells that reside in a licensed noncycling
state (Eward et al, 2004; Wharton et al, 2004).
Increasing grade of tumour was associated with significantly
increased expression of Ki67, Mcm2 and geminin, and lower
expression of the differentiation markers ER and PR (Jonkheere-
Terpstra test, Po0.001 in each case; Table 1 and Figure 2). The
decrease in the Mcm2/Ki67 ratios with increasing grade reflects a
shift in the tumour cell population from a predominantly
nonproliferating licensed state in differentiated tumours to an
actively cycling state in poorly differentiated tumours (median
grade 1: 4.13, grade 2: 2.56, grade 3: 1.85; Po0.001). As in the case
of well-differentiated tumours, normal breast has a similarly high
Mcm2/Ki67 ratio (median: 11.16) indicative of a licensed
nonproliferating state. The shift from the latter state to the
proliferating state with increasing tumour grade is also reflected by
the increase in geminin expression, indicating that cells are
engaging in DNA synthesis and progressing through S–G2–M
phase (median grade 1: 2.00%, grade 2: 6.48%, grade 3: 17.14%;
Po0.001). Higher tumour grade is also associated with an increase
in the geminin/Ki67 ratio, signifying a shortening of G1 phase for
the more malignant phenotype (grade 1: 0.29 vs grade 3: 0.36;
P¼0.07) and an increase in HER-2 expression (P¼0.05).
Interestingly, higher expression levels of geminin were observed
in invasive ductal carcinoma compared to lobular carcinoma
(median: 12.41 vs 7.14%; Po0.02).
A logistic regression model shows that none of the markers
including Ki67, Mcm2, geminin, ER, PR, HER-2, nor the Mcm2/
Ki67 or geminin/Ki67 ratios, have any statistically significant
association with lymph node metastasis (Table 3). Moreover, the
low values of Spearman’s correlation coefficient indicate that there
is no association between tumour size and any of these markers
(Table 4). The results of the Mann–Whitney test indicate that
Table 1 Marker expression (median percentage of cells positive) across
different tumour grades
Marker Normal tissue Grade 1 Grade 2 Grade 3
Ki67 2.14 10.26 17.11 43.66
Mcm2 35.32 55.17 70.16 96.91
Geminin 0.76 2.00 6.48 17.14
ER 22.13 100 100 13.88
PR 19.60 100 98.11 0
Mcm2/Ki67 11.16
a 4.13 2.56 1.85
Gem/Ki67 0.46
a 0.29 0.32 0.36
aFigures unreliable as Ki67 staining % is low.
Ki67 Mcm2 Geminin
Geminin
Ki67
Mcm2
100
80
60
40
20
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Labelling index (%)
Samples
A
B
Figure 1 (A) Photomicrographs of paraffin-embedded tissue sections of
normal premenopausal breast immunohistochemically stained with anti-
bodies against Ki67, Mcm2 and geminin (original magnification,  400). A
high proportion of epithelial cells of the terminal duct lobular unit express
Mcm2, a subpopulation Ki67 and only a minority geminin. The higher
labelling index for Mcm2 compared to Ki67 reflects an additional replication
licensed but nonproliferating growth fraction, identified by Mcm2 but not
the standard proliferation marker Ki67. (B) Ki67, Mcm2 and geminin
labelling indices for individual cases of normal premenopausal breast. Case
1 showing high levels of Ki67, Mcm2 and geminin expression is a patient
who had a prophylactic mastectomy for BRCA1. All other cases of
reduction mammoplasty show higher expression of Mcm2 compared to
Ki67 and geminin.
DNA replication licensing in breast cancer
A Shetty et al
1297
British Journal of Cancer (2005) 93(11), 1295–1300 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
spresence of LVI is associated with decreased expression of ER
(P¼0.02) and PR (P¼0.05) but no association with the other
markers.
Linear regression models indicate that Ki67, Mcm2 and the
Mcm2/Ki67 ratio are statistically significantly associated with
the surrogate outcome measure NPI, but that this association
does not apply to geminin or the geminin/Ki67 ratio. The Ki67
and Mcm2 labelling indices and the Mcm2/Ki67 ratio are
Table 2 Clinicopathological details of invasive breast cancer series
Clinicopathological feature Frequency
Age
o40 12
40–59 54
460 54
Size (mm)
o11 12
11–20 36
21–30 35
31–40 17
440 16
Unknown 4
Lymph node stage
No 63
Yes 49
Unknown 8
Grade
11 2
25 3
35 5
NPI score
o3.4 22
3.4–5.4 62
45.4 28
Unknown 8
Lymphovascular invasion
Absent 69
Present 45
Unknown 6
Tumour type
Invasive ductal 93
Lobular 20
Mucinous 4
Mixed 3
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Figure 2 Ki67, Mcm2, geminin, ER and PR labelling indices (median
percentage of cells stained positive) depicted across breast cancer grades
1–3. Increasing differentiation (from grade 3 to grade 1) is associated with
decreasing Ki67, Mcm2 and geminin expression and increasing ER and PR
labelling indices.
Ki67 Mcm2 Geminin
Grade 1
Grade 2
Grade 3
Figure 3 Photomicrographs of paraffin-embedded tissue sections of
breast cancer grades 1–3 immunohistochemically stained with antibodies
against Ki67, Mcm2 and geminin (original magnification,  400). Increasing
tumour grade is associated with increasing Ki67, Mcm2 and geminin
expression. Note that Mcm2 expression is approaching 100% in grade 3
cancers.
Table 3 Relationship between median marker expression and lymph
node metastasis
Lymph node metastasis
Marker No Yes
Ki67 32.42 36.35
Mcm2 68.74 75.01
Geminin 11.52 13.10
ER 74.75 62.59
PR 60.40 50.45
Mcm2/Ki67 4.15 3.23
Gem/Ki67 0.43 0.41
Table 4 Correlation between markers and tumour size using Spear-
man’s correlation coefficient
Marker Correlation
Ki67 0.10
Mcm2 0.11
Geminin 0.09
ER  0.03
PR  0.02
Mcm2/Ki67  0.01
Gem/Ki67  0.01
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shighly correlated with one another, with Mcm2 being the
single most important predictor of NPI score (Po0.001).
Importantly, only 12% in the variation of NPI is explained by
this marker (the value of R
2 from the linear regression model equal
to the square of Pearson’s correlation coefficient between NPI and
Mcm2), a consequence of the very high levels of Mcm2 expression
in higher-grade tumours (median grade 3: 96.91%; Table 1;
Figure 2).
DISCUSSION
We and others have demonstrated that repression of origin
licensing is a powerful downstream mechanism by which
metazoan cells lower proliferative capacity (Yoshida et al, 1982;
Stoeber et al, 2001; Blow and Hodgson, 2002; Eward et al, 2004).
Withdrawal of cells from the mitotic cell cycle into quiescent (G0),
terminally differentiated or senescent ‘out-of-cycle’ states is
coupled to downregulation of Mcm2–7 and the origin licensing
repressor geminin (Stoeber et al, 2001; Eward et al, 2004; Wharton
et al, 2004). Expression profiling of these RLFs in normal
premenopausal breast revealed an unusual replication phenotype.
Although the growth fraction identified by the standard prolifera-
tion marker Ki67 is small, a large number of mammary epithelial
cells within the TDLU express Mcm2, indicating that a large
number of cells appear to be licensed and therefore ‘in-cycle’.
Failure of these licensed cells to progress through the cell cycle is
confirmed in this study through their failure to express the S–G2–
M marker geminin. We have previously reported that during
pregnancy the proportion of MCM-expressing lobular cells
increases to greater 95%, coinciding with cell expansion and also
including the myoepithelial cell population. This was followed by
dramatic downregulation of the MCM licensing factors as cells
entered the terminally differentiated lactating phenotype (Stoeber
et al, 2001). It thus appears that persistence of Mcm2–7 expression
in nonproliferating breast may be an evolutionary adaptation
allowing a rapid response to pregnancy, and it remains to be
determined whether this primed state may predispose the breast to
genotoxic insult and facilitate the transition to uncontrolled cell
proliferation. In this context it is noteworthy that the prophylactic
mastectomy specimen for BRCA1 showed higher levels of Mcm2
expression than the reduction mammoplasty specimens
(Figure 1B, case 1).
Our analysis of the DNA replication licensing pathway in
breast cancer has revealed that MCM expression is coupled to
the differentiation status of tumours. The hierarchical stem cell
model of tumour growth proposes that neoplasms represent
stem cell systems in which a minority of cells has the prolifera-
tive capacity to maintain the tumour, whereas the majority
demonstrate features of differentiation and have limited prolif-
erative potential (Reya et al, 2001; Clarke et al, 2003; Dontu et al,
2003). We have demonstrated that loss of proliferative capacity
during early stages of differentiation is linked to downregulation
of Cdc6, Cdt1, geminin and Ki67. In contrast, downregulation
of Mcm2–7 is a late event when cells enter the terminally
differentiated state (Eward et al, 2004). Thus, combinatorial ana-
lysis of RLFs and Ki67 allows identification of three distinct
replication phenotypes: proliferating cells (Cdc6, Cdt1, Mcm2–7,
geminin and Ki67 positive), differentiating cells (Mcm2–7
positive; Cdc6, Cdt1, geminin and Ki67 negative) and terminally
differentiated cells (Cdc6, Cdt1, Mcm2–7, geminin and Ki67
negative). The particular replication phenotype observed in breast
cancer is entirely in keeping with the hierarchical stem cell model
of tumour growth, the uncoupling of Mcm2 expression with
geminin and Ki67 expression increasing with a higher degree of
differentiation.
We have recently shown that geminin expression provides an
estimate of the S–G2–M growth fraction in dynamic cell
populations, and that the geminin/Ki67 ratio defines the relative
length of G1 (Eward et al, 2004). Proliferating cells with a short
G1 phase will approximate to a geminin/Ki67 ratio of B1, whereas
cells with a prolonged G1 will approximate to a ratio of B0
(Wharton et al, 2004). Interestingly, we observed a nonsignificant
trend in the geminin/Ki67 ratio between grade 1, grade 2 and grade
3 tumours, with increasing values signifying an accelerated G1
phase in the more poorly differentiated tumours (Table 1). The
lower levels of geminin expression in lobular vs ductal carcinoma
suggest a higher rate of cell cycle progression in tumours of the
latter type.
We have previously reported that the replication licensing
pathway is deregulated early in epithelial carcinogenesis, and that
the increased growth fraction detected by Mcm2–7 antibodies
compared to Ki67 antibodies can be exploited for cancer detection
and surveillance (Williams et al, 1998; Freeman et al, 1999; Stoeber
et al, 1999, 2002; Wharton et al, 2001; Going et al, 2002). We and
others have also shown that MCM proteins can provide prognostic
information in a range of epithelial neoplasms including prostate,
kidney and bladder (Meng et al, 2001; Rodins et al, 2002; Kruger
et al, 2003; Dudderidge et al, 2005). Recently, (Gonzalez et al
(2003) have reported that Mcm2 is a potentially useful and strong
independent prognostic factor in breast cancer. In keeping with
our study, the authors showed that the Mcm2 LI has a positive
association with histological grade and NPI, but not lymph node
stage or LVI. They also noted that the Mcm2 LI is a superior
prognostic marker compared to the Ki67 LI. These findings are
confirmed in our study in which we identified Mcm2 as the single
most important predictor of the surrogate outcome measure NPI.
However, we noted that only 12% in the variation of the NPI is
explained by this marker, a consequence of Mcm2 expression
reaching saturation levels in high-grade tumours. The small value
of 12% suggests that, although there is a statistically significant
positive association between Mcm2 and NPI, there is considerable
variability in NPI that cannot be ascribed to expression of Mcm2
and so the data argue that the usefulness of Mcm2 as a surrogate
measure for NPI is limited. This major constraint in the clinical
utility of Mcm2 as a prognostic marker in breast cancer is also
reflected in the fact that Gonzalez et al found the Mcm2 LI not
superior to the NPI, the present gold standard prognostic
indicator. We have previously demonstrated that the Mcm2–7
subunits of the hexameric MCM complex show identical cell cycle
regulation and are downregulated with similar kinetics during
withdrawal from the proliferative cell cycle (Stoeber et al, 2001).
Thus, our data suggest that Mcm2–7 proteins are severely
constrained as prognostic markers in breast cancer. Interestingly,
we have noted in a separate study that downregulation of Mcm2
and geminin is linked to hormonal blockade and clinical response,
suggesting that although these biomarkers appear to be of limited
value for prognostication, they may have potential as predictors of
therapeutic response in breast cancer (Shetty et al, unpublished
data).
In summary, our investigation of the DNA replication
licensing pathway has provided new insights into the cell cycle
kinetics of normal and neoplastic breast, findings also of
importance for potential therapeutic interventions targeting the
DNA replication licensing machinery (Shreeram et al, 2002;
Shreeram and Blow, 2003; Yoshida et al, 2004). Our study has
shown that although MCM proteins provide prognostic informa-
tion in breast cancer, these markers are likely to be weak
predictors of outcome due to their high-level expression in poorly
differentiated tumours.
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